Innovative drug development projects

  1. Anti-Parkinson drug (DIOL). Market: global – $5 billion; Russian – 2 billion RUB. Doesn’t have analogs in the market, effective in all stages of Parkinson’s disease, provides neuroprotection. Preclinical trials are finished. Clinical trials started in 2019. Patented in Russia, USA, EU.
  2. Antithrombotic drug for preventing atherothrombosis in patients with cardiovascular diseases (GRS). Market: global – $27 billion; Russian – over 20 billion RUB. The first antithrombotic drug in its class – stimulator of guanylate cyclase enzyme, combining antiplatelet, antihypertensive and cardioprotective effects with low toxicity in long-term use. Preclinical trials are finished. Clinical trials started in 2019. Patented in Russia, USA, EU.
  3. Antiviral drug for treating influenza (Camphecin). Market: Russian – over 30 billion RUB. High efficacy in models of influenza, induced by epidemically relevant viral strains (as effective as the world leader tamiflu). Preclinical trials shall be finished in 2018. Patented in Russia.
  4. Anti-inflammatory and analgesic drug for treatment of inflammatory and autoimmune diseases (LIS). Market: global – $10 billion; Russian – over 20 billion RUB. The first drug of its class, inducible NO synthase inhibitor. Preclinical trials shall be finished in 2018. Patented in Russia, USA, EU.
  5. Anti-inflammatory drug (IML). Market: global – $10 billion; Russian – over 20 billion RUB. A unique prodrug based on an indomethacin derivative for treating acute and chronic inflammation. Promising for use in different dosage forms (capsules, injectable, salve). Preclinical trials shall be finished in 2018. Patented in Russia, foreign patenting ongoing.

We offer partnership to pharmaceutical companies interested in adding innovative drugs to their product line.

We invite investors to participate in the completion of our projects and their subsequent commercialization.